{"schema_version":"secwatch.filing_event.v1","accession":"0001711279-25-000037","form_type":"8-K","ticker":"KRYS","cik":"0001711279","company_name":"Krystal Biotech, Inc.","filed_at":"2025-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.428108+00:00","generated_at":"2026-05-22T12:51:26.659319+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Krystal Biotech Presents Preclinical Data on KB801 Gene Therapy for Neurotrophic Keratitis at ARVO 2025","bullets":["KB801 is a topical HSV-1-based vector encoding human NGF for neurotrophic keratitis, disclosed in an 8-K filed May 5, 2025.","In vitro, KB801 transduction of primary human corneal epithelial cells resulted in dose-dependent secretion of mature, functional NGF protein.","In a murine corneal wound model, a single topical KB801 dose produced higher peak NGF (491 pg/eye) and prolonged exposure (t1/2 55.5 hrs) vs. rhNGF (t1/2 83 min).","After eight weekly topical KB801 doses, eyes showed only mild inflammatory infiltrate with no necrosis; all resolved by 27 days post-treatment.","Poster presented at ARVO 2025 Annual Meeting in Salt Lake City, Utah on May 5, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001711279-25-000037","json":"https://secwatch.observer/filing/0001711279-25-000037.json","markdown":"https://secwatch.observer/filing/0001711279-25-000037.md","text":"https://secwatch.observer/filing/0001711279-25-000037.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711279/000171127925000037/0001711279-25-000037-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711279/000171127925000037/krys-20250505.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-22T12:51:26.659319+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}